Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial
Purpose The aim of this study was to investigate the effects of soy isoflavones on serum markers of bone formation and resorption in peritoneal dialysis (PD) patients. Methods In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the soy isoflavo...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2020-07, Vol.52 (7), p.1367-1376 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1376 |
|---|---|
| container_issue | 7 |
| container_start_page | 1367 |
| container_title | International urology and nephrology |
| container_volume | 52 |
| creator | Yari, Zahra Tabibi, Hadi Najafi, Iraj Hedayati, Mehdi Movahedian, Mina |
| description | Purpose
The aim of this study was to investigate the effects of soy isoflavones on serum markers of bone formation and resorption in peritoneal dialysis (PD) patients.
Methods
In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the soy isoflavone or the placebo group. The patients in the soy isoflavone group received 100 mg soy isoflavones daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of the 8th week, 7 ml of blood was obtained from each patient after a 12- to 14-h fast and serum concentrations of bone formation markers (osteocalcin and bone alkaline phosphatase), bone resorption markers [N-telopeptide and receptor activator of nuclear factor kappa B ligand (RANKL)], and osteoprotegerin as an inhibitor of bone resorption were measured.
Results
Serum N-telopeptide concentration decreased significantly up to 27% in the soy isoflavone group at the end of week 8 compared to baseline (
P
= 0.003). Also, serum RANKL concentration reduced significantly up to 17% in the soy isoflavone group at the end of week 8 compared to baseline (
P
= 0.03). These bone resorption markers did not significantly change in the placebo group during the study. There were no significant differences between the two groups in mean changes of serum osteocalcin, bone alkaline phosphatase, and osteoprotegerin.
Conclusion
This study indicates that daily administration of 100 mg soy isoflavone supplement to PD patients reduces serum N-telopeptide and RANKL which are two bone resorption markers.
ClinicalTrials.gov
NCT03773029, 2018. |
| doi_str_mv | 10.1007/s11255-020-02523-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_32488754</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2416726489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-23a1637eb59ca94d5bf8442bcf00f4321f882de0d50fe08cf964d47e077d85a23</originalsourceid><addsrcrecordid>eNqNkU-LFDEQxYMo7rj6BTxIwIuwtFb-ddLeZNhVYcGLnpt0OpGsPcmYZHZYP7219rqCB_EQUiG_V1S9R8hzBq8ZgH5TGeNKdcABj-KiOz4gG6a06Lgy8iHZgADWsZ6LE_Kk1isAGAzAY3IiuDRGK7kh6TwE71qlOdBYc1jsdU4en4lOWNB2KClf-0J3tnzzpdKY6N6X2PDTLnSOdrmpsdK9bdGnVt9SS4tNc97FH36mLqdW8rJg2QqyT8mjYJfqn93dp-TLxfnn7Yfu8tP7j9t3l50TWrWOC8t6of2kBmcHOaspGCn55AJAkIKzYAyfPcwKggfjwtDLWWoPWs9GWS5Oyau1777k7wdf27iL1fllscnnQx25hIENchAS0Zd_oVcZl8bpkGK95r00A1J8pVzJtRYfxn2J6MnNyGC8TWNc0xgxjfFXGuMRRS_uWh-mnZ_vJb_tR8CswNFPOVSHFjp_j2FeSmihb0MDENvY0OSctvmQGkrP_l-KtFjpikT66sufJf8x_0_V3LeR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2416726489</pqid></control><display><type>article</type><title>Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Yari, Zahra ; Tabibi, Hadi ; Najafi, Iraj ; Hedayati, Mehdi ; Movahedian, Mina</creator><creatorcontrib>Yari, Zahra ; Tabibi, Hadi ; Najafi, Iraj ; Hedayati, Mehdi ; Movahedian, Mina</creatorcontrib><description>Purpose
The aim of this study was to investigate the effects of soy isoflavones on serum markers of bone formation and resorption in peritoneal dialysis (PD) patients.
Methods
In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the soy isoflavone or the placebo group. The patients in the soy isoflavone group received 100 mg soy isoflavones daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of the 8th week, 7 ml of blood was obtained from each patient after a 12- to 14-h fast and serum concentrations of bone formation markers (osteocalcin and bone alkaline phosphatase), bone resorption markers [N-telopeptide and receptor activator of nuclear factor kappa B ligand (RANKL)], and osteoprotegerin as an inhibitor of bone resorption were measured.
Results
Serum N-telopeptide concentration decreased significantly up to 27% in the soy isoflavone group at the end of week 8 compared to baseline (
P
= 0.003). Also, serum RANKL concentration reduced significantly up to 17% in the soy isoflavone group at the end of week 8 compared to baseline (
P
= 0.03). These bone resorption markers did not significantly change in the placebo group during the study. There were no significant differences between the two groups in mean changes of serum osteocalcin, bone alkaline phosphatase, and osteoprotegerin.
Conclusion
This study indicates that daily administration of 100 mg soy isoflavone supplement to PD patients reduces serum N-telopeptide and RANKL which are two bone resorption markers.
ClinicalTrials.gov
NCT03773029, 2018.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-020-02523-w</identifier><identifier>PMID: 32488754</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Alkaline phosphatase ; Biomarkers - blood ; Bone growth ; Bone Remodeling - drug effects ; Bone resorption ; Bone turnover ; Double-Blind Method ; Female ; Humans ; Isoflavones ; Isoflavones - pharmacology ; Life Sciences & Biomedicine ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; NCT ; NCT03773029 ; Nephrology ; Nephrology - Original Paper ; Osteocalcin ; Osteogenesis ; Osteoprotegerin ; Peritoneal Dialysis ; Peritoneum ; Phosphatase ; Renal Insufficiency, Chronic - blood ; Renal Insufficiency, Chronic - therapy ; Science & Technology ; TRANCE protein ; Urology ; Urology & Nephrology ; Young Adult</subject><ispartof>International urology and nephrology, 2020-07, Vol.52 (7), p.1367-1376</ispartof><rights>Springer Nature B.V. 2020</rights><rights>Springer Nature B.V. 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000537379800003</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c375t-23a1637eb59ca94d5bf8442bcf00f4321f882de0d50fe08cf964d47e077d85a23</citedby><cites>FETCH-LOGICAL-c375t-23a1637eb59ca94d5bf8442bcf00f4321f882de0d50fe08cf964d47e077d85a23</cites><orcidid>0000-0001-9094-7772 ; 0000-0001-8887-1385</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-020-02523-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-020-02523-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,782,786,27931,27932,28255,41495,42564,51326</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32488754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yari, Zahra</creatorcontrib><creatorcontrib>Tabibi, Hadi</creatorcontrib><creatorcontrib>Najafi, Iraj</creatorcontrib><creatorcontrib>Hedayati, Mehdi</creatorcontrib><creatorcontrib>Movahedian, Mina</creatorcontrib><title>Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>INT UROL NEPHROL</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Purpose
The aim of this study was to investigate the effects of soy isoflavones on serum markers of bone formation and resorption in peritoneal dialysis (PD) patients.
Methods
In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the soy isoflavone or the placebo group. The patients in the soy isoflavone group received 100 mg soy isoflavones daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of the 8th week, 7 ml of blood was obtained from each patient after a 12- to 14-h fast and serum concentrations of bone formation markers (osteocalcin and bone alkaline phosphatase), bone resorption markers [N-telopeptide and receptor activator of nuclear factor kappa B ligand (RANKL)], and osteoprotegerin as an inhibitor of bone resorption were measured.
Results
Serum N-telopeptide concentration decreased significantly up to 27% in the soy isoflavone group at the end of week 8 compared to baseline (
P
= 0.003). Also, serum RANKL concentration reduced significantly up to 17% in the soy isoflavone group at the end of week 8 compared to baseline (
P
= 0.03). These bone resorption markers did not significantly change in the placebo group during the study. There were no significant differences between the two groups in mean changes of serum osteocalcin, bone alkaline phosphatase, and osteoprotegerin.
Conclusion
This study indicates that daily administration of 100 mg soy isoflavone supplement to PD patients reduces serum N-telopeptide and RANKL which are two bone resorption markers.
ClinicalTrials.gov
NCT03773029, 2018.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alkaline phosphatase</subject><subject>Biomarkers - blood</subject><subject>Bone growth</subject><subject>Bone Remodeling - drug effects</subject><subject>Bone resorption</subject><subject>Bone turnover</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Isoflavones</subject><subject>Isoflavones - pharmacology</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>NCT</subject><subject>NCT03773029</subject><subject>Nephrology</subject><subject>Nephrology - Original Paper</subject><subject>Osteocalcin</subject><subject>Osteogenesis</subject><subject>Osteoprotegerin</subject><subject>Peritoneal Dialysis</subject><subject>Peritoneum</subject><subject>Phosphatase</subject><subject>Renal Insufficiency, Chronic - blood</subject><subject>Renal Insufficiency, Chronic - therapy</subject><subject>Science & Technology</subject><subject>TRANCE protein</subject><subject>Urology</subject><subject>Urology & Nephrology</subject><subject>Young Adult</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkU-LFDEQxYMo7rj6BTxIwIuwtFb-ddLeZNhVYcGLnpt0OpGsPcmYZHZYP7219rqCB_EQUiG_V1S9R8hzBq8ZgH5TGeNKdcABj-KiOz4gG6a06Lgy8iHZgADWsZ6LE_Kk1isAGAzAY3IiuDRGK7kh6TwE71qlOdBYc1jsdU4en4lOWNB2KClf-0J3tnzzpdKY6N6X2PDTLnSOdrmpsdK9bdGnVt9SS4tNc97FH36mLqdW8rJg2QqyT8mjYJfqn93dp-TLxfnn7Yfu8tP7j9t3l50TWrWOC8t6of2kBmcHOaspGCn55AJAkIKzYAyfPcwKggfjwtDLWWoPWs9GWS5Oyau1777k7wdf27iL1fllscnnQx25hIENchAS0Zd_oVcZl8bpkGK95r00A1J8pVzJtRYfxn2J6MnNyGC8TWNc0xgxjfFXGuMRRS_uWh-mnZ_vJb_tR8CswNFPOVSHFjp_j2FeSmihb0MDENvY0OSctvmQGkrP_l-KtFjpikT66sufJf8x_0_V3LeR</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Yari, Zahra</creator><creator>Tabibi, Hadi</creator><creator>Najafi, Iraj</creator><creator>Hedayati, Mehdi</creator><creator>Movahedian, Mina</creator><general>Springer Netherlands</general><general>Springer Nature</general><general>Springer Nature B.V</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9094-7772</orcidid><orcidid>https://orcid.org/0000-0001-8887-1385</orcidid></search><sort><creationdate>20200701</creationdate><title>Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial</title><author>Yari, Zahra ; Tabibi, Hadi ; Najafi, Iraj ; Hedayati, Mehdi ; Movahedian, Mina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-23a1637eb59ca94d5bf8442bcf00f4321f882de0d50fe08cf964d47e077d85a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alkaline phosphatase</topic><topic>Biomarkers - blood</topic><topic>Bone growth</topic><topic>Bone Remodeling - drug effects</topic><topic>Bone resorption</topic><topic>Bone turnover</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Isoflavones</topic><topic>Isoflavones - pharmacology</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>NCT</topic><topic>NCT03773029</topic><topic>Nephrology</topic><topic>Nephrology - Original Paper</topic><topic>Osteocalcin</topic><topic>Osteogenesis</topic><topic>Osteoprotegerin</topic><topic>Peritoneal Dialysis</topic><topic>Peritoneum</topic><topic>Phosphatase</topic><topic>Renal Insufficiency, Chronic - blood</topic><topic>Renal Insufficiency, Chronic - therapy</topic><topic>Science & Technology</topic><topic>TRANCE protein</topic><topic>Urology</topic><topic>Urology & Nephrology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yari, Zahra</creatorcontrib><creatorcontrib>Tabibi, Hadi</creatorcontrib><creatorcontrib>Najafi, Iraj</creatorcontrib><creatorcontrib>Hedayati, Mehdi</creatorcontrib><creatorcontrib>Movahedian, Mina</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yari, Zahra</au><au>Tabibi, Hadi</au><au>Najafi, Iraj</au><au>Hedayati, Mehdi</au><au>Movahedian, Mina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><stitle>INT UROL NEPHROL</stitle><addtitle>Int Urol Nephrol</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>52</volume><issue>7</issue><spage>1367</spage><epage>1376</epage><pages>1367-1376</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>Purpose
The aim of this study was to investigate the effects of soy isoflavones on serum markers of bone formation and resorption in peritoneal dialysis (PD) patients.
Methods
In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the soy isoflavone or the placebo group. The patients in the soy isoflavone group received 100 mg soy isoflavones daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of the 8th week, 7 ml of blood was obtained from each patient after a 12- to 14-h fast and serum concentrations of bone formation markers (osteocalcin and bone alkaline phosphatase), bone resorption markers [N-telopeptide and receptor activator of nuclear factor kappa B ligand (RANKL)], and osteoprotegerin as an inhibitor of bone resorption were measured.
Results
Serum N-telopeptide concentration decreased significantly up to 27% in the soy isoflavone group at the end of week 8 compared to baseline (
P
= 0.003). Also, serum RANKL concentration reduced significantly up to 17% in the soy isoflavone group at the end of week 8 compared to baseline (
P
= 0.03). These bone resorption markers did not significantly change in the placebo group during the study. There were no significant differences between the two groups in mean changes of serum osteocalcin, bone alkaline phosphatase, and osteoprotegerin.
Conclusion
This study indicates that daily administration of 100 mg soy isoflavone supplement to PD patients reduces serum N-telopeptide and RANKL which are two bone resorption markers.
ClinicalTrials.gov
NCT03773029, 2018.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>32488754</pmid><doi>10.1007/s11255-020-02523-w</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9094-7772</orcidid><orcidid>https://orcid.org/0000-0001-8887-1385</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1623 |
| ispartof | International urology and nephrology, 2020-07, Vol.52 (7), p.1367-1376 |
| issn | 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_pubmed_primary_32488754 |
| source | MEDLINE; SpringerNature Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Adult Aged Aged, 80 and over Alkaline phosphatase Biomarkers - blood Bone growth Bone Remodeling - drug effects Bone resorption Bone turnover Double-Blind Method Female Humans Isoflavones Isoflavones - pharmacology Life Sciences & Biomedicine Male Medicine Medicine & Public Health Middle Aged NCT NCT03773029 Nephrology Nephrology - Original Paper Osteocalcin Osteogenesis Osteoprotegerin Peritoneal Dialysis Peritoneum Phosphatase Renal Insufficiency, Chronic - blood Renal Insufficiency, Chronic - therapy Science & Technology TRANCE protein Urology Urology & Nephrology Young Adult |
| title | Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T18%3A24%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20isoflavones%20on%20bone%20turnover%20markers%20in%20peritoneal%20dialysis%20patients:%20a%20randomized%20controlled%20trial&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Yari,%20Zahra&rft.date=2020-07-01&rft.volume=52&rft.issue=7&rft.spage=1367&rft.epage=1376&rft.pages=1367-1376&rft.issn=0301-1623&rft.eissn=1573-2584&rft_id=info:doi/10.1007/s11255-020-02523-w&rft_dat=%3Cproquest_pubme%3E2416726489%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2416726489&rft_id=info:pmid/32488754&rfr_iscdi=true |